• DeepHealth, a wholly owned RadNet subsidiary, won FDA 510(k) clearance for an AI-powered breast ultrasound product.
• Product targets lesion detection, characterization, reporting automation; accuracy above 98%, cancer-detection sensitivity up 8%, interpretation time cut 37%.
• Commercial US rollout begins immediately; customers can seek reimbursement under an existing Category III CPT code.
• Deployment planned across RadNet centers by year-end; more than 700,000 annual breast ultrasound exams may qualify for reimbursement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RadNet Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607301615PRIMZONEFULLFEED9801259) on July 30, 2026, and is solely responsible for the information contained therein.